Trials / Recruiting
RecruitingNCT06986785
A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with lenvatinib in patients with advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Lenvatinib | 8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD. |
Timeline
- Start date
- 2025-06-24
- Primary completion
- 2027-05-01
- Completion
- 2027-12-01
- First posted
- 2025-05-23
- Last updated
- 2025-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06986785. Inclusion in this directory is not an endorsement.